|Home | About | Journals | Submit | Contact Us | Français|
Resistin-like molecule alpha or found in inflammatory zone protein (Fizz1) is increased in pulmonary epithelial cells and also in limited amounts by other lung cells during various lung injuries and fibrosis. However, the direct role of Fizz1 produced in the pulmonary epithelium has not been determined.
Fizz1 Transgenic mice (CCSP/Fizz1) were generated that overexpress Fizz1 in the lung epithelium under the control of a doxycycline (Dox) inducible lung epithelial cell specific promoter Scgb1a1 (Clara cell secretory protein, CCSP). Histology and FACS analysis of lung cells were used to identify the direct effects of Fizz1 in the transgenic mice (Dox treated) when compared with control (CCSP/-) mice. Intratracheal bleomycin sulfate or silica in saline and saline alone were used to study the role of Fizz1 during bleomycin- and silica-induced pulmonary fibrosis in CCSP/Fizz1 and CCSP/- mice. Weight change, pulmonary inflammation, and fibrosis were assessed 10days post bleomycin or 28days post silica challenge.
When CCSP/Fizz1 mice were fed Dox food, elevated Fizz1 protein was detected in lung homogenates by western blot. Lungs of mice in which Fizz1 was induced in the epithelium contained increased lung cells staining for CD11c and F4/80 by FACS analysis consistent with increased dendritic cells however, no changes were observed in the percentage of interstitial macrophages compared to CCSP/- controls. No significant changes were found in the lung histology of CCSP/Fizz1 mice after up to 8weeks of overexpression compared to CCSP/- controls. Overexpression of Fizz1 prior to challenge or following challenge with bleomycin or silica did not significantly alter airway inflammation or fibrosis compared to control mice.
The current study demonstrates that epithelial cell derived Fizz1 is sufficient to increase the bone-marrow derived dendritic cells in the lungs, but it is not sufficient to cause lung fibrosis or alter chemical or particle-induced fibrosis.
Lung remodeling in the distal airspace and parenchyma is characterized by excessive extracellular matrix deposition and accumulation of apoptosis-resistant and collagen producing myofibroblasts. Currently there are no effective therapeutic treatments available for pulmonary fibrosis highlighting the importance of identifying targetable cells, fibrogenic pathways and molecules to design therapeutic approaches and to use as biomarkers of disease progression. Multiple rodent models have been established that recapitulate mechanisms leading to pulmonary fibrosis and identify cells, pathways and growth factors mediating pulmonary fibrosis [1-6]. Resistin-like molecules or found in inflammatory zone (FIZZ) are a family of cysteine-rich secreted small proteins which have been shown to play an important role in the cell differentiation implicated in the pathophysiology of chronic diseases including obesity, type 2 diabetes, helminth infections and forms of pulmonary fibrosis [7-12]. The family consists of 4 members: Relm-α/Fizz1, Relm-β/Fizz2, Resistin/Fizz3, and Relm-γ/Fizz4. In the lung, Fizz1 is induced in environments with Th2-cytokine preponderance and induction of Fizz1 occurs through IL13/IL4-driven STAT 6 activation. In hypoxic injury, Fizz1 is induced independent of IL4 . The expression pattern of Fizz1 resembles resistin suggesting functional overlap between mouse derived Fizz1 and human resistin . In vitro studies demonstrate that Fizz1 activates type I collagen expression in fibroblasts via a notch1-dependent pathway . In addition, Fizz1 transforms fibroblasts to collagen producing myofibroblasts and induces anti-apoptotic responses in myofibroblasts contributing to excess myofibroblast accumulation and production of extracellular matrix proteins in the lung .
Previous studies provide conflicting evidence regarding the in vivo involvement of Fizz1 in promoting forms of pulmonary fibrosis [7-10,14]. Fizz1 overexpression using adenoviral gene transfer or hypoxia increased the recruitment of bone marrow derived cells (BMD) to the lung and increased vascular remodeling with fibrotic changes localized to pulmonary arteries [8,15]. In a mouse model of hypoxia-induced pulmonary hypertension, the recruitment of BMD cells was associated with a concomitant increase in Fizz1 levels in the lung. However, Fizz1 knockout mice challenged with the parasitic eggs of S. mansoni eggs displayed heightened pulmonary fibrosis associated with increases in CD4+ Th2 cell derived IL-4 and IL-13 [7,9] suggesting that Fizz1 is a negative regulator of pro-fibrotic Th2 cytokines induced by parasitic infections.
Transforming growth factor-α (TGFα) is a ligand for the epidermal growth factor receptor (EGFR) and transgenic mice conditionally expressing TGFα specifically in the lung epithelium develop progressive fibrosis accompanied with cachexia, changes in lung mechanics and secondary pulmonary hypertension [16,17]. Microarray analysis of whole lung homogenates in the TGFα mice demonstrates increases in Fizz1 transcripts following the induction of the transgene . Fizz1 was originally reported to be induced primarily in lung epithelial cells in Ova  and Aspergillus models  and in a hypoxia model . Fizz1 is also induced in macrophages in asthma models and eosinophils in asthma and helminth infection models [7,19]. More recently Fizz1 has been reported in alternatively activated macrophages . Recent studies using Fizz1 reporter mice confirm that lung epithelial cells are a major source for Fizz1 in the lung . As the direct role of Fizz1 in the pathogenesis of lung fibrosis remains elusive and the lung epithelial cells appear to be key producers of Fizz1, we generated transgenic mice which conditionally expresses Fizz1 under the control of a doxycycline (Dox) inducible lung epithelial cell specific promoter Scgb1a1 (Clara cell secretory protein, CCSP). This promoter has been shown to lead to transgene expression in the bronchial, bronchiolar epithelium and to a lesser extent in alveolar epithelium [21,22]. This pattern of gene expression mimics the cellular sites reported for Fizz1 expression in the lung [7,18,19]. Transgenic mice constitutively expressing Fizz1 in the pulmonary epithelium were used to determine effects on cellular influx in the lung, lung remodeling, and experimental models of pulmonary fibrosis using bleomycin or silica.
Transgenic mice were generated by cloning full length Fizz1 cDNA from mouse lung RNA and inserting into the (TetO)7-CMV promoter. The (TetO)7-CMV Fizz1 transgene consists of seven copies of tet operator DNA binding sequence linked to a minimal CMV promoter, the mouse Fizz1 cDNA, and SV40 polyadenylation signal. The construct was injected into mouse oocytes generating (TetO)7-CMV Fizz1+/+ mice. All mice were derived from the FVB/NJ inbred strain. Animals were housed under specific pathogen-free conditions and handled in accordance with protocols approved by the Institutional Animal Care and Use Committee of the Children's Hospital Research Foundation and the University of Cincinnati Medical Center. Bitransgenic Fizz1 transgenic mice (abbreviated as CCSP/Fizz1) were produced by mating Single transgenic Clara Cell Specific Protein-rtTA+/− mice (abbreviated as CCSP/-) with (TetO)7-CMV Fizz1+/+ mice. To induce Fizz1 expression bitransgenic mice were administered doxycycline (Dox) food (62.5mg/kg). The fold increase in detectable Fizz1 was determined by comparing pixels from the off Dox and On Dox lanes in Figure1 using a phosphorimager and ImageQuant software .
Transgenic mice were identified using PCR primers specific for each transgene as follows: 5' primer in the rat CCSP promoter, 5' ACT GCC CAT TGC CCA AAC AC-3'; 3' primer in rtTA coding sequence, 5'-AAA ATC TTG CCA GCT TTC CCC-3'. Mice were identified for (TetO)7-CMV Fizz1 transgene with PCR sense primer, 5' TGA TGG TCC CAG TGA ATA CTG ATG-3'; anti-sense primer, 5' GGT CCA TGG TGA TAC AAG GGA CAT-3'. Amplification of PCR products for CCSP and Fizz1 were performed by denaturation at 94°C for 5 minutes and then 30 cycles of amplification at 94°C for 30 seconds, 57°C for 30 seconds and 72°C for 30 seconds, followed by 7 minutes extension at 72°C.
Proteins in the total lung homogenates (50μg) from the CCSP/Fizz1 mice on Dox or off Dox for 2weeks were separated using SDS-PAGE and proteins transferred to PVDF membrane as described earlier . Fizz1 protein was detected using a rabbit polyclonal anti-mouse Fizz1 antibody (Peprotech, Rocky Hill, NJ, USA) and HRP-conjugated anti-rabbit secondary antibody. Recombinant Fizz1 protein was used as a positive control and signal developed using a chemiluminescent kit.
Bleomycin-induced pulmonary fibrosis was performed as described earlier with few modifications . In brief, CCSP/- and CCSP/Fizz1 mice were kept on Dox for two weeks to establish Fizz1-induced changes in the lung. On day 14, mice were anaesthetized with a xylazine and ketamine cocktail and given 0.15 U bleomycin sulfate (EMD) in saline or saline alone via the I.T. route. On day 10 post bleomycin, mice were sacrificed and the lungs were collected for biochemical and histological analysis.
For silica-induced pulmonary fibrosis, mice on Dox were anaesthetized with a xylazine and ketamine cocktail and given 3mg of 5 micron size sterile silica (US silica, Beverly Springs, WV, USA) per mouse in 50μl saline or saline alone via the I.T. route. On day 28, mice were sacrificed and the lungs were collected for biochemical and histological analysis.
Lungs were inflation fixed using 4% paraformaldehyde and stained with hematoxylin and eosin (H&E) and masson trichrome kit as described earlier .
Fibrosis in the lungs was quantified using a modified assay for determination of hydroxyproline in tissues . In brief, the left lobe of lung was weighed and hydrolyzed in 4ml of 6N HCl overnight at 110°C. Hydrolyzed samples were neutralized with 1N NAOH. For colorization, chloramine-T (0.05M) and the aldehyde-perchloric acid reagent were added and samples placed in hot water bath at 60°C for 25min. The standard hydroxyl-L-proline (EMD) solutions prepared and treated identically to the samples to read at 550nm for samples and standards. Sample concentrations were determined from the standard curve.
Mice challenged with bleomycin or silica were euthanized with sodium pentobarbital (65mg/kg) and lungs were lavaged sequentially with 0.7 and 0.5ml aliquots of PBS, pooled and used to determine total cell counts and for cytospin preparations to determine macrophage cell counts. Cells were isolated from the broncho-alveolar lavage fluid (BALF) by centrifugation at 1250rpm-5 minutes and the cell pellet resuspended in 1ml of PBS and cells were counted using hemocytometer.
Total lung cells were prepared for FACS staining by mincing the lung in a complete RPMI medium and subjected to collagenase digestion for 30 minutes at 37°C. After digestion, lung cells were filtered through 100μm filter and counted by hemocytometer. About 1 million cells were incubated with CD16/CD32 (Fc block) and stained for surface antigens CD11b, CD11c, F4/80 and CD45. Cell populations were analyzed using FACS Calibur and Flow Jo as described earlier .
Total RNA was extracted from lung tissue using the RNeasy Mini Kit from Qiagen (Qiagen Sciences, Valencia, CA) as described previously . Primers used were: HPRT 5'-GCCCTTGACTATAATGAGTACTTCAGG-3' (forward), 5'-TTCAACTTGCGCTCATCTTAGG-3' (reverse); Fizz1 5'-CCCTCCACTGTAACGAAGACTC-3' (forward), 5'-CACACCCAGTAGCAGTCATCC-3' (reverse).
All data was analyzed with Prism (Version 5; GraphPad). Student t-test used to compare between two groups. One-way ANOVA with Tukey`s Multiple Comparison post-test is used to compare more than two experimental groups and data were considered statistically significant for P values less than 0.05.
Transgenic mice were generated by cloning full length Fizz1 cDNA from mouse lung RNA and inserting into the CMV-TetO promoter (TetO-Fizz1 mice). 4 different lines were generated and screened for increases in Fizz1 transcripts. Selected TetO-Fizz1 mice were bred to CCSP-rtTA activator mice to generate bitransgenic CCSP-rtTA/tetO-Fizz1 mice (CCSP/Fizz1) conditionally expressing epithelial Fizz1 protein when fed Dox containing food (Figure1A). To demonstrate the proper translation and maturation of overexpressed Fizz1 transcripts, CCSP/Fizz1 mice were administered Dox food for 2weeks and Fizz1 protein measured in lung homogenates by western blot. CCSP/Fizz1 mice on Dox demonstrated about 14.1 fold increases in the signal intensity at 9.5kDa corresponding to a mature Fizz1 protein in lung homogenates over lung homogenates from mice not treated with Dox (Figure1B). Previous studies demonstrate that target gene expression in bitransgenic mice using the reverse tetracycline transactivator (rtTA) expressed under the control of CCSP promoter is restricted to alveolar Type II cells and non-ciliated bronchial and bronchiolar epithelial cells but not in ciliated cells[27-29]. The highest-expressing line of founders was subsequently used in all studies.
To assess the direct effects of Fizz1 overexpression, CCSP/Fizz1 mice were fed Dox food for 14days. CCSP/Fizz1 mice on Dox demonstrated increased total cell counts compared to mice without Dox (Figure2A). There were no differences between groups in cytospin differential with 99% macrophages recovered.
Fizz1 has previously been reported to increase recruitment of bone marrow derived cells to the lung . To assess if epithelial overexpression of Fizz1 altered bone-marrow-derived cell populations in the lung, total lung cells from lung homogenates of CCSP/Fizz1 mice on and off Dox were stained for markers of hematopoietic cells (CD45) and monocytes/macrophages (CD11b). CCSP/Fizz1 mice on Dox demonstrated increases in both the percentage and total number of cells positive for both CD45 and CD11b (Figure2B and and2C).2C). Total lung cells were also stained for CD11c and F4/80, which are markers distinguishing dendritic cells from alveolar (AM) and interstitial macrophages (IM) . CCSP/Fizz1 mice on Dox demonstrated a more than two fold increase in dendritic cells with no significant changes in AM and IM (Figure2D and and2E).2E). Together, these experiments show that overexpression of Fizz1 in the lung resulted in an increased accumulation of bone-marrow-derived dendritic cells, consistent with previous reports [8,30]. We measured the transcripts for chemokines CCL3 and CCL19, which are known to be involved in the recruitment of DCs to the lung. CCL3 and CCL19 transcript levels are not changed in Fizz1 overexpressing mice compared to control mice at day 5 on Dox (Additional file 1: Figure S 1). Therefore, mechanisms involved in the accumulation of DCs in Fizz1 overexpressing mice could be direct, due to Fizz1, or alternatively other unknown modulators could be induced which would make the effects of Fizz1 indirect.
To assess the direct effects of Fizz1 overexpression on lung remodeling, lung histology was assessed in CCSP/Fizz1 mice at selected intervals up to 8weeks of continuous expression. There were no detectable changes in collagen deposition, myofibroblasts accumulation or vascular remodeling between CCSP/Fizz1 mice on Dox compared to controls (Figures3). Together, these data suggest that Fizz1 increases the migration of bone-marrow derived cells to the lung but has no direct effects on pulmonary remodeling in normal mice without known inflammatory injuries.
We next assessed if overexpression of lung epithelial Fizz1 altered the phenotype of inflammatory models of pulmonary fibrosis. Fizz1 transcripts in wild type mice 10days following bleomycin injury were increased more than 6-fold from controls confirming activation of Fizz1 with bleomycin injury (Figure4A). CCSP/Fizz1 mice were fed Dox food for 14days to establish Fizz1-induced changes in the lung cells. Mice were challenged with intratracheal bleomycin on day 14 and continued on Dox for another 10days before mice were euthanized (Figure4B). CCSP/Fizz1 mice on Dox receiving bleomycin had a greater loss in body weight compared with CCSP/- control mice on Dox and bleomycin (Figure4C). Total BAL cells were increased in both CCSP/Fizz1 and CCSP/- controls at day10 post bleomycin challenge (Figure4D). Compared with saline treated controls there were no differences in BAL cell differentials between bleomycin-challenged groups (Figure4E). Bleomycin-induced lung injury has been shown to cause the recruitment of CD11b+ DCs which may contribute to the fibrotic responses in the lung . In agreement, bleomycin-induced injury has resulted in the accumulation of CD45+CD11b+ cells in the lungs of CCSP/- and CCSP/Fizz1 mice exposed to bleomycin compared to saline treated CCSP/- mice (Additional file 1: Figure S2). Fizz1 overexpression had no effect on the percentage of CD45+CD11b+ cells compared to CCSP/- mice exposed to bleomycin. Masson trichrome staining did not demonstrate differences in the degree or distribution of matrix deposition in the lungs following bleomycin in the CCSP/Fizz1 and CCSP/- mice challenged with bleomycin (Figure5A). Total lung weight and hydroxyproline levels in the lungs were increased in the CCSP/Fizz1 and CCSP/- mice following bleomycin, but there were no differences between groups (Figure5B and and5C).5C). Together, these data indicate Fizz1 overexpression resulted in greater loss in body weight following bleomycin, but did not alter the inflammatory cells or the total collagen content in the lung, suggesting that Fizz1 had no effect on bleomycin-induced pulmonary fibrosis.
Occupational exposure to crystalline silica has been shown to form silicotic nodules characterized by localized inflammation, fibroblast proliferation and excess collagen deposition [33-35]. Resident and recruited macrophages have been shown to play a pivotal role in developing silicotic nodules, and increased proportions of Fizz1 expressing macrophages are found in bronchoalveolar lavage specimens from animals and humans with silica dust exposure [35-39]. To determine whether Fizz1 overexpression altered silica-induced pulmonary inflammation and fibrosis, CCSP/Fizz1 were fed Dox food then challenged with intratracheal silica and continued on Dox for another 28days following silica instillation. CCSP/Fizz1 and CCSP/- control mice on Dox developed granulomatous nodules largely comprising of macrophages but there were no differences in the numbers or distribution of nodules within groups (Figure6A). Total BAL cells were increased in both CCSP/Fizz1 and CCSP/- controls but there were no differences between groups and no differences in cell differential (Figure6B). Total macrophage numbers in BAL were increased in CCSP/Fizz1 mice compared to CCSP/- mice exposed to silica (Figure6C). Mason’s trichrome staining did not demonstrate differences in the degree or distribution of matrix deposition in the lungs following silica in either group (Figure7A). Total lung weight and hydroxyproline levels in the lungs were increased in the CCSP/Fizz1 and CCSP/- controls following silica, but there were no differences between groups (Figure7B and and7C).7C). Together, these data indicate that Fizz1 overexpression did not alter inflammation or the total collagen content in the lungs of silica-exposed mice.
The current study demonstrates that constitutive overexpression of Fizz1 in lung epithelial cells increases the percentage of bone marrow derived hematopoietic cells in the lung. Our findings support earlier work where Fizz1 was overexpressed in the lung using a recombinant adeno-associated viral (AAV) vector, and bone marrow derived cells of hematopoietic lineage were recruited to the smooth muscle layer of pulmonary vessels . In the current study we further characterized the changes in the lung cell population with Fizz1 overexpression using FACS analysis and demonstrated that Fizz1 induced recruitment was associated with a higher percentage of cells staining for both CD11c and F4/80, which are markers associated with dendritic cells. This is the first study to demonstrate a direct role for Fizz1 produced in lung epithelial cells in vivo in the recruitment of dendritic cells into the lung and further supports a role for the Fizz family as a chemoattractant for bone marrow derived cells. Recently, Fizz2 has also been shown to directly cause chemoattraction of bone-marrow-derived dendritic cells, and lung recruitment of bone-marrow-derived cells including dendritic cells was impaired in Fizz2 knockout mice .
Our study demonstrated that epithelial overexpression of Fizz1 without a concomitant lung injury was not associated with changes in lung architecture or lung fibrosis. The role of Fizz1 in vivo in altering pulmonary fibrosis is unclear. Fizz1 overexpression with adenoviral vectors increased thickening and collagen surrounding pulmonary arteries . However, Fizz1 knockout mice challenged with the parasitic eggs of S. Mansoni eggs displayed heightened pulmonary fibrosis suggesting that Fizz1 is a negative regulator of parasite induced pro-fibrotic Th2 cytokines and in this model Fizz1 is anti-fibrotic . Another recent study using Fizz1 KO mice demonstrates that Fizz1 was largely dispensable during Aspergilus fumigatous allergen-induced production of Th2 cytokines, eosinophilia and airway remodeling .
The migration of myeloid cells from the bone marrow to the lung has been shown to regulate inflammation and the pathogen burden in the lung. Data over the past decades also supports a role for bone marrow derived fibrocytes in contributing to the cellular accumulation of mesenchymal cells and extracellular matrix . Although, myeloid cells have been shown to migrate into the lung, the secretory mediators involved in the migration and maturation to different cell subsets, along with their functional role remains an area of active investigation. The present study does not establish whether Fizz1 chemoattraction of dendritic cells is due to Fizz1 alone or Fizz1 regulation or interaction with other chemoattractant molecules. The myeloid cell subsets that populate in the lung include dendritic cells, alveolar macrophages and interstitial macrophages. Notably, findings of this study demonstrate that Fizz1 overexpression increased dendritic cells in the lung without altering lung architecture. Dendritic cells are critical members of adaptive immunity in the lung involved in antigen processing and mediating immunity responses. Lung dendritic cells have been shown to accumulate in human fibrotic lung disease and bleomycin-induced fibrosis, but have not been shown to independently and directly cause lung remodeling. The present study shows that Fizz1 mediated attraction of dendritic cells was not adequate to influence lung fibrosis. Fizz1 overexpression has no effect on CD45+CD11b+cells in the lung during bleomycin-induced injury. Future studies are warranted to identify the roles of Fizz1-recruited dendritic cells in immunity against bacterial and viral pathogens and also infections associated injury and remodeling in the lung.
As we were not able to demonstrate direct remodeling from Fizz1 overexpression, we examined if Fizz1 overexpression altered fibrosis in known inflammatory models. Fizz1 was overexpressed in the lung prior to challenge with bleomycin or silica. Both models induce inflammatory changes leading to fibrosis; however the inflammatory responses are different with bleomycin resulting in an oxidative injury associated with neutrophil influx, while silica leads to macrophage-related activation and formation of inflammatory nodules. With both challenges, overexpression of Fizz1 did not alter the degree of lung remodeling. In the bleomycin injury, expression of Fizz1 did cause a greater loss of body weight. Although the mode of action is not known, these data further support the concept that lung epithelial cell produced Fizz1 has systemic effects consistent with effect on systemic recruitment of bone marrow derived cells. While the precise mode of activity is not known, Fizz1 has been shown to alter IL-13 induced chemokine levels, inhibit nerve growth factor neuronal survival, and cause bone marrow cell migration in a transwell assay through interactions with Bruton’s tyrosine kinase. Thus Fizz1 may act directly or indirectly by influences on cytokine or growth factor induced regulation.
In spite of an increase in Fizz1 transcripts induced by bleomycin in the lung, the results of our study do not support a role for Fizz1 produced in the lung epithelium as a direct cause of lung fibrosis. In the present study, single instillations of bleomycin and silica were used which cause a slowly resolving inflammation leading to diffused fibrosis or nodular fibrosis. In hypoxic injury, the injury is continuous and leads to pulmonary hypertension. Fizz1 may act in a localized fashion to increase fibrotic responses around pulmonary arterioles during chronic hypoxia but not to increase granuloma formation around S. mansoni parasites or retained silica particles. In addition, the differences in the activation of immune pathways, cellular sites of Fizz1 production such as macrophages and eosinophils, and the amount of Fizz1 produced may be responsible for observed differences between studies. Lack of observable histological and hydroxyproline differences in bleomycin or silica-induced lung remodeling in Fizz1 overexpressing mice could be due to doses of bleomycin or silica. While the doses used in this study have been used in previous studies, the tested dose may mask or not be a sufficient dose to show Fizz1 effects. Alternatively, other members of the Fizz family may be involved in pulmonary fibrosis. When challenged with bleomycin, Fizz2 knockout mice show a decrease in the absolute number of total BAL cells, cytokine gene expression and extracellular matrix deposition than control mice .
The findings in the current study indicated that epithelial overexpression of Fizz1 promoted the recruitment of bone marrow-derived dendritic cells into the lung, but did not directly induce fibrosis or alter inflammatory models of fibrosis.
FACS, Fluorescent activated cell sorting; FIZZ, Found in inflammatory zone; RELM, Resistin like molecule; AM, Alveolar macrophages; IM, Intersttial macrophages; Dox, Doxycycline; Ova, Ovalbumin; CCSP, Clara cell secretory protein; PCR, Polymerase chain reaction; IT, Intratracheal; IL, Interleukin.
The authors declared that they have no competing interest.
SKM, TRK and WDH were responsible for experimental design, data analysis and manuscript preparation. SKM performed the bleomycin and silicosis challenges. RE performed RT-PCR for chemokines, FACS analysis and manuscript preparation. JAK generated the Fizz1 transgene and transgenic mice and KRD performed mouse husbandry, breeding and genotyping. SS and CD performed histological staining, mouse husbandry, breeding and biochemical studies. All authors read and approved the final manuscript
Figure S1. Fizz1 overexpression has no significant effect on CCL3 and CCL19 transcripts in the lung. CCSP/Fizz1 mice were fed with or without DOX for 5days and transcripts for CCL3 and CCL19 were measured in the total lung transcripts using Real Time PCR. Figure S2. Fizz1 overexpression has no effect on bleomycin-induced increases in CD45+CD11b+cells in the lung. Total lung cells were stained with anti-CD11b and anti-CD45 antibodies at day10 post bleomycin or saline. Gating strategy of CD45+CD11b+cells in the lungs of bleomycin exposed and Fizz1 overexpressing mice compared to CCSP/- mice exposed to bleomycin or saline. Bleomycin treatment has increased the percentage of CD45+CD11b+cells. Fizz1 overexpression had no modifying effects on bleomycin-induced increase in the percentage of CD45+CD11b+cells.
The authors thank the veterinary services at CCHMC for their expert care of mice used in this study. This study was partially supported by AI083599, 5R01HL086598, P50HL107159 (TRK and WDH) and AHA Scientist Development Grant 12SDG9130040 (SKM).